{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T07:24:14Z","timestamp":1787383454989,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.genhosppsych.2026.04.005","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:14:47Z","timestamp":1776467687000},"page":"196-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review"],"prefix":"10.1016","volume":"100","author":[{"given":"Gabrielle F.M.","family":"Lovell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Vasudeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana K.","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Di Luch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0005","article-title":"The multivariate effect of ketamine on PTSD: systematic review and Meta-analysis","volume":"13","author":"Du","year":"2022","journal-title":"Front Psych"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211056743","article-title":"Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders","volume":"11","author":"Whittaker","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0015","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and Meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 \u2013 january 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","article-title":"Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a Meta-analysis of randomized clinical trials","volume":"72","author":"Kryst","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0025","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18r12475","article-title":"Oral ketamine for depression: a systematic review","volume":"80","author":"Rosenblat","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0030","unstructured":"Kim J, Mierzwinski-Urban M. Ketamine for treatment-resistant depression or post-traumatic stress disorder in various settings: A review of clinical effectiveness, safety, and guidelines [internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Mar 1. PMID: 29533569."},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0035","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4103\/psychiatry.IndianJPsychiatry_484_18","article-title":"Efficacy of ketamine therapy in the treatment of depression","volume":"61","author":"Mandal","year":"2019","journal-title":"Indian J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0040","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jpsychires.2021.02.028","article-title":"Ketamine specifically reduces cognitive symptoms in depressed patients: an investigation of associated neural activation patterns","volume":"136","author":"Stippl","year":"2021","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0045","first-page":"1","article-title":"Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression","author":"Hossein","year":"2025","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0050","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & Meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0055","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.25m15789","article-title":"Comparative effects of repeated ketamine infusion versus intranasal esketamine in patients with treatment-resistant depression: a retrospective chart review","volume":"86","author":"Meisner","year":"2025","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115865","article-title":"Low dose ketamine infusions for treatment resistant depression: results from a five-year study at a free public clinic in an academic hospital","volume":"335","author":"Gutierrez","year":"2024","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0065","article-title":"Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management","volume":"14","author":"Wilkowska","year":"2023","journal-title":"Front Psych"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HRP.0000000000000330","article-title":"Ketamine in the treatment of obsessive-compulsive disorder: a systematic review","volume":"30","author":"Bandeira","year":"2022","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0075","first-page":"22","article-title":"Effectiveness of ketamine for the treatment of post-traumatic stress disorder \u2013 a systematic review and Meta-analysis. Clin","volume":"21","author":"Almeida","year":"2024","journal-title":"Neuropsychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011709","article-title":"Ketamine infusion therapy for chronic pain management in South Korea: a national survey for pain physicians with a narrative review","volume":"97","author":"Anaya","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/20494637231182804","article-title":"Low-dose ketamine infusions for chronic pain management: does this qualify as evidence-based practice?","volume":"17","author":"Griffiths","year":"2023","journal-title":"Br J Pain"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/psychoactives4030020","article-title":"Ketamine and esketamine in psychiatry: a comparative review emphasizing neuroplasticity and clinical applications","volume":"4","author":"Mikellides","year":"2025","journal-title":"Psychoactives"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0100","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.3390\/pharmaceutics15122773","article-title":"The efficacy and safety of intranasal formulations of ketamine and esketamine for the treatment of major depressive disorder: a systematic review","volume":"15","author":"Boudieu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13256-024-04421-6","article-title":"Features of biliary tract diseases in ketamine abusers: a systematic review of case reports","volume":"18","author":"Teymouri","year":"2024","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0110","first-page":"521","article-title":"Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the american society of regional anesthesia and pain medicine, the american academy of pain medicine, and the american society of anesthesiologists","volume":"43","author":"Cohen","year":"2018","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/17512433.2020.1717947","article-title":"Emerging concepts on the use of ketamine for chronic pain","volume":"13","author":"Yang","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0120","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.cgh.2014.01.041","article-title":"Liver injury is common among chronic abusers of ketamine","volume":"12","author":"Wong","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0125","article-title":"Hepatobiliary complications associated with ketamine use: clinical insights and future directions","volume":"17","author":"Waheed","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0130","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00261-014-0173-2","article-title":"Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings","volume":"39","author":"Yu","year":"2014","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0135","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1751-2980.2010.00424.x","article-title":"Upper gastrointestinal problems in inhalational ketamine abusers","volume":"11","author":"Poon","year":"2010","journal-title":"J Dig Dis"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jhep.2018.03.006","article-title":"Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users","volume":"69","author":"Seto","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0145","series-title":"Guidance for Industry: Drug-Induced Liver Injury\u2014Premarketing Clinical Evaluation","author":"U.S. Food and Drug Administration (FDA)","year":"2009"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0150","first-page":"e52","article-title":"Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series","volume":"52","author":"Lo","year":"2011","journal-title":"Singapore Med J"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0155","doi-asserted-by":"crossref","unstructured":"Bartoli, A.; Cursaro, C.; Seferi, H.; Andreone, P. Secondary sclerosing cholangitis after SARS-CoV2: ICU ketamine use or virus-specific biliary tropism and injury in the context of biliary ischemia in critically ill patients? HMER 2023, 15, 93\u2013112, doi:https:\/\/doi.org\/10.2147\/HMER.S384220, Hepatic Med Evid Res.","DOI":"10.2147\/HMER.S384220"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0160","first-page":"524","article-title":"Ketamine hepatotoxicity: an underappreciated cause of liver damage \u2013 analysis by RUCAM","volume":"13","author":"Thakkar","year":"2025","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0165","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jad.2025.01.054","article-title":"Hepatic adverse events associated with ketamine and esketamine: a population-based disproportionality analysis","volume":"374","author":"Kwan","year":"2025","journal-title":"J Affect Disord"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0170","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40264-021-01120-9","article-title":"Repeated or continuous medically supervised ketamine administration associated with hepatobiliary adverse events: a retrospective case series","volume":"44","author":"Cotter","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0175","series-title":"K\u00e9tamine\u202f: Risque d\u2019atteintes uro-n\u00e9phrologiques, endocriniennes et h\u00e9patiques graves lors d\u2019utilisations prolong\u00e9es et\/ou \u00e0 doses \u00e9lev\u00e9es\u2014Rappel de l\u2019importance du respect du bon usage","author":"Agence nationale de s\u00e9curit\u00e9 du XXXandomized et des produits de sant\u00e9 (ANSM)","year":"2018"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0180","series-title":"Summary Safety Review: Ketamine\u2014Assessing the Potential Risk of Liver and Bile Duct Damage","author":"Health Canada","year":"2020"},{"issue":"7","key":"10.1016\/j.genhosppsych.2026.04.005_bb0185","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/00048674251333577","article-title":"Royal Australian and New Zealand college of psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice","volume":"59","author":"Hussain","year":"2025","journal-title":"Aust New Zeal J Psychiatry"},{"issue":"4","key":"10.1016\/j.genhosppsych.2026.04.005_bb0190","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.genhosppsych.2026.04.005_bb0195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0706743720970860","volume":"66","author":"Swainson","year":"2021","journal-title":"Can J Psychiatry"},{"issue":"5","key":"10.1016\/j.genhosppsych.2026.04.005_bb0200","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaborations tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0210","article-title":"Cochrane handbook for systematic reviews of interventions","volume":"355","author":"Higgins","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0215","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0220","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0225","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/JCP.0000000000000717","article-title":"Oral ketamine in treatment-resistant depression: a clinical effectiveness case series","volume":"37","author":"Al Shirawi","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0230","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241244585","article-title":"Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis","volume":"15","author":"Jiang","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.116334","article-title":"Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R)","volume":"344","author":"Bayes","year":"2025","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0240","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/s41380-024-02478-9","article-title":"Oral Esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension","volume":"29","author":"Smith-Apeldoorn","year":"2024","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0245","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","article-title":"Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study","volume":"48","author":"Zaki","year":"2023","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0250","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0255","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jagp.2017.06.007","article-title":"Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression","volume":"25","author":"George","year":"2017","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0260","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/15622975.2016.1142607","article-title":"Ninety-Six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: a pilot randomised controlled trial","volume":"17","author":"Lenze","year":"2016","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0265","article-title":"Case report: two cases of rhabdomyolysis following esketamine treatment","volume":"15","author":"Zeiss","year":"2024","journal-title":"Front Psych"},{"issue":"10S","key":"10.1016\/j.genhosppsych.2026.04.005_bb0270","doi-asserted-by":"crossref","first-page":"S2781","DOI":"10.14309\/01.ajg.0001046688.87620.5c","article-title":"An atypical case of ketamine-induced liver injury","volume":"119","author":"O\u2019Connor","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"10S","key":"10.1016\/j.genhosppsych.2026.04.005_bb0275","doi-asserted-by":"crossref","first-page":"S1867","DOI":"10.14309\/01.ajg.0001040060.86718.c8","article-title":"Biliary colic in acute ketamine use: a case report","volume":"119","author":"Livitz","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"10S","key":"10.1016\/j.genhosppsych.2026.04.005_bb0280","doi-asserted-by":"crossref","first-page":"S1805","DOI":"10.14309\/01.ajg.0001039640.53178.db","article-title":"Ketamine-induced cholangiopathy: a rare cause of biliary dilatation","volume":"119","author":"Eliava","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.6675","article-title":"A unique case of very low-dose subcutaneous ketamine use: maintenance option of ketamine for treatment-resistant depression","volume":"10","author":"Can","year":"2022","journal-title":"Clin Case Reports"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0290","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy\u2019s law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidem Drug Safe"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0295","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231202723","article-title":"Ketamine for bipolar depression: an updated systematic review","volume":"13","author":"Fancy","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and Meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.genhosppsych.2026.04.005_bb0305","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.25com16021","article-title":"Practitioners providing care for persons with severe mental disorders should routinely screen for metabolic dysfunction-associated steatotic liver disease","volume":"86","author":"McIntyre","year":"2025","journal-title":"J Clin Psychiatry"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834326000769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834326000769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:40:57Z","timestamp":1787380857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834326000769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":61,"alternative-id":["S0163834326000769"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2026.04.005","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2026.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}